THE IMPACT OF METFORMIN AND ROSUVASTATIN ON THE MARKERS OF OXIDATIVE STRESS, GLYCEMIC CONTROL, AND LIPID PROFILE IN RATS WITH STREPTOZOTOCIN-NICOTINAMIDE-INDUCED DIABETES AFTER ACUTE INTRACEREBRAL HEMORRHAGE*

V. I. Zhyluik, A. E. Lievykh, A. I. Shevtsova, V. A. Tkachenko,
Yu. V. Kharchenko, A. H. Myronenko
Dnipro State Medical University, Dnipro, Ukraine
vzhyliuk@gmail.com

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease caused by insulin resistance resulting in elevated blood glucose levels. Poorly controlled diabetes is associated with increased morbidity and mortality in the atherosclerotic cardiovascular disease being the major cause of death [1]. Oxidative modification of proteins (OMP) is one of the early and the most reliable markers of tissue damage in many pathological conditions that involve free radicals, including T2DM. Different tissue proteins but not lipids or nucleic acids are effective traps of the generated reactive oxygen species (ROS) that are overproduced or accumulated in oxidative stress [2]. In addition, the higher levels of glucose and/or lipids in diabetes are responsible for the increased production of highly reactive carbonyl compounds — a condition referred to as «carbonyl stress». Also known as glycotoxins and lipotoxins, these compounds react quickly and damage various molecules in cells forming final products termed AGEs (advanced glycation end products) [3]. Protein carbonylation, one of the most harmful and irreversible protein modifications, is considered to be a key player in the progression of diabetes and associated complications [4].

Although diabetes is an independent risk factor primarily for ischemic stroke, it is also associated with an increased risk of intracerebral hemorrhage (ICH). There is a direct association between ICH probability and diabetes duration. ICH and glycated hemoglobin (HbA1c) appear to have a J-shaped relationship, suggesting that both poor control as well as extreme intensive diabe-
tes control might be associated with increased risk of ICH [5]. Metformin is a basic drug for the treatment of T2DM that lowers blood glucose primarily by decreasing hepatic glucose production and reducing insulin resistance. When used as monotherapy, metformin does not cause hypoglycemia and is thus termed as an «anti-hyperglycemic» [6].

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (atorvastatin, simvastatin, rosuvastatin, etc.) are an important class of therapeutic agents used to control hyperlipidemia and prevent cardiovascular disease in diabetic and nondiabetic patients [7]. Statins were also shown to exhibit non-lipid-modifiable effects called pleiotropic ones, which could be responsible for their additional benefits. The most important pleiotropic anti-atherogenic effects of statins are improvement of endothelial dysfunction, antioxidative properties, anti-inflammatory, anti-proliferative, antithrombotic effects and neoangiogenesis [6].

This comparative research aimed to study the effect of metformin and rosuvastatin on the markers of oxidative stress, glycemic control, and lipid profile in rats with streptozotocin-nicotinamide induced diabetes complicated by an acute intracerebral hemorrhage.

**MATERIALS AND METHODS**

The study was carried out on 38 male Wistar rats weighing 200-250 g. The study design was approved by the Biomedical Ethics Committee of the Dnipro State Medical University (protocol N 8 dated 17.12.2019). Experiments were performed in compliance with the Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes.

Type 2 diabetes mellitus was simulated with a single intraperitoneal injection of nicotinamide (NA, 230 mg/kg body weight) and streptozotocin (STZ, 65 mg/kg body weight) in citrate buffer (pH = 4.5, 0.1 M) to overnight fasted rats [7, 8]. Blood glucose level was measured 72 hours after NA/STZ injection. Animals with values less than 8.3 mmol/L were excluded from the study [7]. ICH in rats was induced by microinjection of 1 μL of bacterial collagenase 0.2 IU/μL (Type IV-S) [9]. On the 60th day after NA/STZ injection, a Hamilton microsyringe was inserted into the striatum of anesthetized rats by the following stereotactic coordinates: 0.2 mm anterior, 2.8–3.0 mm lateral, and 5.5 mm ventral to the bregma.

According to the result of the oral glucose tolerance test, all rats with a similar degree of glycemia were randomly divided into five groups: group A — negative control / naive (saline, 5 ml/kg/day, n = 8); group B — positive control 1 (NA/STZ + saline, 5 ml/kg/day, n = 9); group C — positive control 2 (NA/STZ + ICH + saline, 5 ml/kg/day, n = 7); group D — animals that received metformin, 250 mg/kg/day (NA/STZ + ICH + Met, n = 7); group E — animals that received rosuvastatin, 15 mg/kg/day (NA/STZ + ICH + Ros, n = 7).

The studied drugs were administered intragastrically for 20 days, starting from the 50th day after the induction of diabetes. Blood glucose level was measured with the blood glucose meter Bionime Rightest GM300 (Bionime Corporation, Switzerland) in blood samples from the tail vein. The oral glucose tolerance test was performed on the 69th day of the study. Overnight fasted animals were given 2 g/kg body weight of 20 % glucose solution by intragastric gavage 2 hours after drug administration. The area under the glycemic curve (AUC) was calculated using GraphPad Prism 9.0 software and expressed as min x mmol/L. On the 70th day of the study, blood samples were obtained by intracardiac puncture from the right ventricle of the heart of anesthetized rats.

Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and glucose were measured in blood serum using diagnostic kits («Reagent»; Ukraine). Homocysteine (Hcy) level in serum was measured by enzymatic method using «Homocysteine, enzymatic cycling» kit («DIALAB® G.m.b.H.» Wr. Neudorf, Austria). These markers were assessed with a semiautomatic biochemical analyzer HTI BioChem SA (High Technology Inc., USA).

Glycated hemoglobin (HbA1c) was measured spectrophotometrically in whole blood.
The level of advanced glycated end products (AGEs) was measured by fluorescence method [12], using Hoefer DQ 2000 Fluorometer (USA) with fixed wavelengths (excitation/emission = 365 nm/460 nm). The results were expressed as arbitrary units (AU) per mg of protein.

Statistical data analysis was performed by GraphPad Prism 9.0 (GraphPad Software, Inc., La Jolla, CA, USA, GPS-2169913-THSGDF1FF). All results are expressed as mean (M) ± SD. Statistical significance (p < 0.05) was determined by a two-tailed Student t-test or one-way ANOVA for normally distributed variables; and Mann–Whitney U-test or Kruskal–Wallis H-test for non-normally distributed variables.

RESULTS AND THEIR DISCUSSION

The results of the study showed that NA/STZ-treated rats had increased HbA1c levels by 37.3 % (p < 0.05) compared to the animals in the negative control group on the 70th day of the experiment. Whereas this marker was higher by 53.9 % (p < 0.001) in rats with T2DM and ICH as compared to the negative control group (Fig. 1A). Metformin, but not rosuvastatin, significantly reduced HbA1c levels by 20.3 % (p < 0.05) in comparison with group B (positive control 1), and by 28.9 % (p < 0.01) in comparison with group C (positive control 2). The difference in HbA1c levels between group E and group C was statistically insignificant.

Fig. 1B shows the changes in blood glucose AUC in all groups of rats on the 69th day of the experiment. According to the data obtained, the course of T2DM (group B) led to the development of glucose tolerance, as evidenced by an increase in glycemic AUC by 58.1 % (p < 0.001). Moreover, modeling ICH (group C) did not affect glucose tolerance in this test significantly, and AUC value was higher by 75 % (p < 0.001) as compared to the negative control group.

Additionally, it was found that the development of T2DM in rats led to a significant increase in basal glycemia, but ICH did not affect its severity. Under these conditions, none of the studied drugs had a hypoglycemic effect (Fig. 1C).

It should be noted that administration of rosvastatin, in contrast to metformin, had no effect on the markers of glycemic control in rats with acute ICH with T2DM (Fig. 1A, 1B, 1C).

According to the data in Table, the diabetic animals were characterized by changes in lipid profile. Interestingly, there was a moderate lowering in TC levels in rats with T2DM, which progressed under conditions of acute brain hemorrhage, and TC was decreased by 22.2 % (p < 0.05) in comparison with the negative control group. Moreover, TG levels were 31.4 % higher (p < 0.05), and the high-density lipoprotein (TG/HDL) ratio was 73.3 % higher (p < 0.05) than the values of intact animals. The ratio of triglyceride to TG/HDL is considered as a biomarker of insulin resistance and atherogenicity [13, 14]. And the change of this marker could be an additional confirmation of T2DM and atherogenesis in our study. Metformin did not affect TC levels but reduced TG content by 20.2 % (p < 0.05) and TG/HDL ratio by 31.9 % (p < 0.05) in comparison with the group of animals with ICH. Whereas, administration of rosvastatin, in contrast to metformin, resulted in the reduction of TC levels by 16.5 % (p < 0.05) as compared to the intact rats. Also, rosvastatin significantly reduced TG content by 33.6 % (p < 0.01) and the atherogenicity index (TG/HDL) by 39.4 % (p < 0.05), which indicates its primarily antiatherogenic activity.

Homocysteine, as a predictor of endothelial dysfunction and atherogenesis, also
showed a clear upward trend in diabetic rats, with acute ICH having no effect on its level (Fig. 2A). Experimental treatment with the studied drugs also did not affect homocysteine content in rats with T2DM and ICH.

Acute ICH in rats with T2DM led to a statistically significant rise in the advanced glycation end products (AGEs) level by 53.9 % (p < 0.01) in comparison with the negative control group (Fig. 2B). At the same time, there was an increase in the content of the markers of oxidative modification of proteins (APH and KPH) by 10.5 % (p < 0.01) and 38.7 % (p < 0.001), respectively (Fig. 2C). It should be noted that both metformin and rosuvastatin almost equivalently reduced AGEs levels in serum by 35.4 % (p < 0.05) and 35.1 % (p < 0.05). Whereas none of the studied drugs affected the APH content and only metformin reduced the KPH content by 21.2 % (p < 0.05).

The results of this study show that acute ICH in rats with T2DM may impair glucose and lipid metabolism, and additionally contribute to the development of oxidative or carbonyl stress in the blood. Although the obtained differences between the groups of positive control were characterized only by a persistent trend. It should be noted that the studied drugs exhi-

![Graph A](image1.png)

**HbA1c**

- A — HbA1c level (on the 70th day of the experiment).
- B — glycemic AUC (on the 69th day of the experiment).
- C — serum glucose level (on the 70th day of the experiment).

**Notes:** * — p < 0.05, ** — p < 0.01, *** — p < 0.001.

![Graph B](image2.png)

**AUC**

- A - naive (n=8)
- B - NA/STZ+saline (n=9)
- C - NA/STZ+ICH+saline (n=7)
- D - NA/STZ+ICH+Met (n=7)
- E - NA/STZ+ICH+Ros (n=7)

![Graph C](image3.png)

**Glucose**

- A - naive (n=8)
- B - NA/STZ+saline (n=9)
- C - NA/STZ+ICH+saline (n=7)
- D - NA/STZ+ICH+Met (n=7)
- E - NA/STZ+ICH+Ros (n=7)
**Effects of metformin and rosuvastatin on lipid profile in rats with T2DM and ICH (M ± SD)**

<table>
<thead>
<tr>
<th>Experimental groups, n</th>
<th>TC, mmol/l</th>
<th>HDL, mmol/l</th>
<th>TG, mmol/l</th>
<th>TG/HDL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control, saline (n = 8)</td>
<td>2.34 ± 0.389</td>
<td>0.43 ± 0.098</td>
<td>0.53 ± 0.114</td>
<td>1.32 ± 0.162</td>
</tr>
<tr>
<td>Positive control 1, (n = 9)</td>
<td>2.07 ± 0.289</td>
<td>0.39 ± 0.098</td>
<td>0.54 ± 0.226</td>
<td>1.46 ± 0.214</td>
</tr>
<tr>
<td>Positive control 2, saline (n = 7)</td>
<td>1.82 ± 0.393*</td>
<td>0.29 ± 0.079**</td>
<td>0.69 ± 0.150*</td>
<td>2.73 ± 0.533*</td>
</tr>
<tr>
<td>Metformin, (n = 7)</td>
<td>2.05 ± 0.285</td>
<td>0.35 ± 0.104</td>
<td>0.55 ± 0.100**</td>
<td>1.73 ± 0.243</td>
</tr>
<tr>
<td>Rosuvastatin, (n = 7)</td>
<td>1.95 ± 0.141*</td>
<td>0.40 ± 0.068*</td>
<td>0.46 ± 0.133**</td>
<td>1.20 ± 0.167*</td>
</tr>
</tbody>
</table>

Notes:
* — p < 0.05, ** — p < 0.01 (versus Negative control);
# — p < 0.05, ## — p < 0.01 (versus Positive control 1);
@ — p < 0.05, @@ — p < 0.01 (versus Positive control 2).

---

**Fig. 2.** Effects of metformin and rosuvastatin on the markers of oxidative stress in rats with T2DM and ICH. All data are presented as M ± SD.

A — homocysteine (Hcy) level. B — advanced glycated end products (AGEs).
C — markers of oxidative modification of proteins (aldehydephenylhydrazones (APH) and ketonephenylhydrazones (KPH)).

Notes: * — p < 0.05, ** — p < 0.01, *** — p < 0.001.
bit their typical pharmacological properties — rosvastatin in relation to lipid profile, and metformin in relation to glycemic control [6, 7]. Moreover, the effect of metformin, in contrast to rosvastatin, on the manifestations of carbonyl stress was not only limited to a decrease in AGEs content, but also was accompanied by a significant decrease in the levels of late markers of oxidative modification of the proteins. At the same time, both drugs did not produce any effect on homocysteine metabolism.

CONCLUSIONS

1. Acute intracerebral hemorrhage in rats with streptozotocin-nicotinamide-induced diabetes can intensify the manifestations of oxidative stress and worsen glycemic control and lipid profile, although the obtained differences were characterized only by a persistent trend.
2. Under these conditions, rosvastatin improves lipid profile and reduces the levels of advanced glycated end products in serum but does not affect glycemia and content of the markers of oxidative modification of proteins.
3. Metformin reduces oxidative stress as well as improves both glycemic status and triglyceride level in rats with type 2 diabetes mellitus and intracerebral hemorrhage.
4. Metformin and rosvastatin do not affect hyperhomocysteinemia caused by type 2 diabetes mellitus.

REFERENCES

This comparative research aimed to study the effect of metformin and rosuvastatin on the levels of biochemical markers of oxidative stress, glycemic control, and lipid profile in rats with type 2 diabetes mellitus (T2DM) complicated by a brain hemorrhage.

Materials and methods. T2DM was simulated with a single intraperitoneal injection of nicotinamide and streptozotocin (NA/STZ) to male Wistar rats (n = 38). Intracerebral hemorrhage (ICH) was induced by microinjection of 1 μL of bacterial collagenase 0.2 IU/μL into the striatum. Animals were randomized into 5 groups: negative control, intact rats; positive control 1, NA/STZ; positive control 2, NA/STZ + ICH; metformin, 250 mg/kg + NA/STZ + ICH; rosuvastatin, 15 mg/kg + NA/STZ + ICH. Drug effects were assessed by the area under the glycemic curve (AUC), the content of glucose, glycated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), homocysteine (Hcy), advanced glycation end products (AGEs), and the markers of oxidative modification of proteins — aldehyde- and ketonephenylhydrazones (APH/KPH) in blood serum.

Results. It was found that brain hemorrhage in rats with T2DM can intensify the manifestations of oxidative modification of molecules and worsen glycemic control and lipid profile. Under these conditions, rosuvastatin improved lipid metabolism and reduced the levels of AGEs by 35.1 % but did not affect glycemia and content of APH/KPH. Metformin reduced oxidative stress (AGEs by 35.4 %, KPH by 21.2 %) as well as improved both glycemic status and lipid profile (TG level by 20.2 %, TG/HDL ratio by 31.9 %). Both drugs did not produce any effect on Hcy level.

Thus, metformin in conditions of T2DM complicated by acute ICH has advantages over rosuvastatin in relation to the markers of oxidative modification and glycemic control.

Key words: type 2 diabetes mellitus, intracerebral hemorrhage, advanced glycation end products, oxidative modification of proteins, homocysteine, rosuvastatin, metformin.